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The National Cancer Registry is now in its 27th year of data-collection and, for the years 1994 onwards, has provided 
surveillance of trends in cancer incidence, mortality, treatment, survival, and prevalence, along with associated clinical 
and demographic aspects of the patient population. Although statistics for the most recent years are not yet finalised, 
estimates of case numbers are provided for the most recent three-year period (2018-2020) based on a combination 
of data up to 2018 and population updates for years up to 2020. 
 
This year’s report estimates that numbers of invasive cancers (excluding non-melanoma skin cancer) have risen to 
about 24,753 cases diagnosed annually during 2018-2020 (13,152 males and 11,641 females), or 36,907 cases 
including all invasive cancers. These figures represent a doubling of case-numbers since the registry’s early years 
(1994-1996). However, previous reports have shown that rates of cancer, corrected for population and age, have 
begun to level off or even decline for many cancer types, thus increases in case numbers in more recent years largely 
reflect population growth and ageing.  
 
Just over 9,000 deaths from cancer occurred per year during 2015-2017, or about 1 death for every 3 cancers 
diagnosed (excluding non-melanoma skin cancers). Based on the international CONCORD-3 study (some results of 
which are summarised in this report), survival of Irish cancer patients ranks in the top half of EU countries surveyed 
for most cancer types. Ireland’s ranking within Europe has improved over time, but there is still room for improvement. 
 
Improvements in survival have contributed to ongoing increases in the numbers of cancer survivors, and we estimate 
that over 190,000 cancer survivors previously diagnosed with an invasive cancer (other than non-melanoma skin 
cancer) were alive at the end of 2018. This figure is equivalent to almost 4% (1 in 25) of the Irish population, and is 
likely to exceed 200,000 by the end of 2020. 
 
On the whole, the implications of the above trends are largely positive, in terms of an individual’s risk of developing 
or dying from cancer, although the population-level burden of cancer is strongly influenced by population changes. As 
the cancer projections report published by NCRI last year highlighted, there is uncertainty as to the magnitude of 
further increases in the annual number of cases diagnosed. A further analysis was published by the NCRI this year, 
funded by the Irish Cancer Society [1], to assess the proportions of cancer attributable to established risk factors with 
a view to mitigation of future increases in cancer through action on modifiable risk factors. 
 
As noted in last year’s report, the National Cancer Registry’s new Strategy aims to build on the decades of cancer 
surveillance already undertaken, to further strengthen the registry’s role in supporting cancer control initiatives in 
Ireland. This will of course depend on the ongoing efforts of our staff, in collaboration with hospitals and other 
components of the health services in Ireland, and further improvements in efficiencies (especially in terms of use of 
electronic data) will be needed to match the ever-increasing volume and complexity of cancer control measures and 
associated data collection. 
 
 
 
 
 
                     Professor Kerri Clough-Gorr 
                  Director, National Cancer Registry 
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1. REPORT AT A GLANCE 
  
 
  
 
 
  
 
 
 
Who are we, and what do we do? 
 
The National Cancer Registry of Ireland (NCRI) works 
on behalf of the Department of Health and collects 
information from all hospitals in Ireland on the 
number of persons diagnosed with cancer and the 
types of cancer they have. 
NCRI also follows up the numbers dying from their 
cancer or from other causes. All the patient’s 
personal and private details are removed before 
summaries of this information are made available to 
public and health professionals through our annual 
cancer report and other reports on our website. 
 
How are the numbers reported? 
 
The process of collecting and checking all of this 
information is performed largely by hand, even with 
increasing use of electronic data sources. Our staff 
collect cancer diagnosis information and then use 
an agreed system of coding (The International 
Classification of Diseases) to group the cancers into 
different types. 
After a process of collating diverse information from 
Irish hospitals and assigning it to the correct person 
followed by anonymisation, the annual cancer 
report is published. 
 
What have we found? 
 
Over the years 2018-2020 the average number of ‘registered tumours’ in males and females is estimated at almost 
45,000 per year. Just over 1 in 2 (c.25, 000 excluding non-invasive tumours and non-melanoma skin cancers) are life-
changing invasive cancers which often require extensive treatment. 
 
Cancer cases: 
Annual average 2018-2020 
 
Percentages represent the proportion of ‘all 
registered tumours’.  
 
For example, non-melanoma skin cancer made up 
23% (almost 1 in 4) of all registered tumours in 
females and 31% (almost 1 in 3) in males 
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Top four most common incident cancers during 2018-2020 
Males 
 
Females 
 
 
  
 
 
 
 
 
 
How many people 
were diagnosed with 
cancer? 
 
 On average, 45,753 cancers or related tumours were diagnosed 
each year during 2018-2020.  
 Approximately 18% (almost 1 in 5) of these were non-invasive 
neoplasms (in situ carcinomas, tumours of uncertain behaviour and 
benign brain and CNS tumours). 
 27% (just over 1 in 4) were non-melanoma skin cancers.  
 Invasive cancers (including NMSC) were estimated to average 
36,907 cases per year during 2018-2020. 
 The figure most often quoted in international comparisons (“all 
invasive cancer, excluding NMSC”) was estimated at 24,793 cases 
(13,152 male and 11,641 female) diagnosed annually during 2018-
2020, or 55% (about 1 in 2) of all registered tumours.  
 
What are the most 
common cancers? 
 
 Excluding NMSC, prostate and female breast cancer were the most 
commonly diagnosed invasive cancers overall, and each comprised 
almost one-third of all invasive cancers in men and women 
respectively during the period 2018-2020. 
 Colorectal (bowel) cancer, lung cancer, melanoma of skin and NHL 
were the 2nd, 3rd, 4th and 5th most common cancers in males, 
respectively. 
 Lung cancer, colorectal cancer, melanoma of skin, and uterine cancer 
(corpus uteri) were the 2nd, 3rd, 4th and 5th most common cancers 
in females respectively 
 
 
2020 Annual Report   National Cancer Registry Ireland 
 
7 
 
 
  
 
  
  
Top four most common causes of cancer death during 2015-2017 
Males  Females 
 
 
 
 
 
 
  
How many people die 
of cancer? 
 
 Of all deaths occurring in 2017, 31% (almost 1 in 3) were attributable to 
cancer. Another 30% and 13% were attributable to diseases of the 
circulatory and respiratory systems respectively. 
 On average there were 9,063 deaths per year from invasive cancer 
(4,799 in males, 4,264 in females) during the period 2015-2017, or 
9,281 deaths per year from any tumour type. 
 
What are the most 
common cancer 
deaths? 
 
 Lung cancer was the leading cause of cancer death in both sexes 
during 2015-2017.  
 In males, cancer of the bowel, prostate and oesophagus were the 2nd, 
3rd, and 4th most common categories of cancer deaths, respectively.  
 In females, cancer of the breast, bowel and ovary were the 2nd, 3rd and 
4th most common categories of cancer deaths, respectively. 
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Number of cancer survivors The six most common cancers among cancer survivors 
  
Total number =190,309 (100%)  
 
 
  
How many previously 
diagnosed cancer 
patients are still alive? 
 Over 190,000 cancer patients or former cancer patients were alive 
in Ireland at the end of 2018 (about 3.9% or 1 in 25 of the Irish 
population) and this is likely to exceed 200,000 by the end of 2020. 
 The top six most common cancers among survivors were: breast 
cancer (23% of all cancer survivors), prostate cancer (21%), 
colorectal cancer (12%) and skin melanoma (7%), non-Hodgkin 
lymphoma (4%) and lung cancer (3%) which together make up 70% 
of all cancer survivors. 
 These figures exclude non-melanoma skin cancers.  
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5 –year net survival  for the period 
2012-2016 
  
*Colon & colorectral cancer survival excludes 
carcinoids of the appendix. 
See Figure 5-1 for 10-year net survival 
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What proportion of cancer patients are still alive at 
5 years after diagnosis? 
The six major cancers with highest 5-
year survival are: 
 Testis 
 Prostate 
 Melanoma of skin 
 Thyroid 
 Hodgkin lymphoma 
 Breast (female) 
 
 The six major cancers with lowest 5-
year survival are: 
 Pancreas 
 Liver 
 Lung 
 Oesophagus 
 Brain 
 Stomach 
 
These proportions continue to improve 
over time, across almost all cancers, 
based on data available since 1994. 
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IRELAND’S RANK WITHIN THE EUROPEAN UNION FOR 5-YEAR NET SURVIVAL: 
BY CANCER TYPE AND PERIOD (CONCORD-3) 
 
2000-2004 2005-2009 2010-2014 
top half 
2010-2014? 
rank 
comparison 
2010-2014 
vs.  
2000-2004 
oesophagus 5th of 22 3rd of 23 4th of 22 yes ↑ 
stomach 19th of 23 16th of 24 9th of 24 yes ↑ 
rectum 14th of 23 13th of 24 9th of 24 yes ↑ 
pancreas 12th of 22 12th of 23 8th of 23 yes ↑ 
lung 15th of 23 12th of 24 6th of 24 yes ↑ 
melanoma skin 9th  of 23 10th of 24 8th of 24 yes ↑ 
cervix 18th of 23 21st  of 24 16th of 24  ↑ 
prostate 10th of 23 10th of 24 6th of 24 yes ↑ 
brain-adults 6th  of 22 5th of 23 4th of 23 yes ↑ 
brain-children 11th of 21 12th of 20 7th of 22 yes ↑ 
lymphoid-adults 11th of 23 6th of 24 6th of 24 yes ↑ 
acute lymphoblastic leukaemia-
children 
11th of 23 11th of 23 10th of 23 yes ↑ 
colon 13th of 23 11th of 24 13th of 24  ↔ 
breast 16th of 23 15th of 24 16th of 24  ↔ 
ovary 23rd of 23 22nd of 24 23rd of 24  ↔ 
liver 8th of 23 10th of 23 9th of 23 yes ↓ 
myeloid-adults 3rd of 23 4th of 24 5th of 24 yes ↓ 
lymphoma-children 1st of 21 2nd of 21 4th of 21 yes ↓ 
The figures in the table show Ireland’s survival rank within the number of EU28 countries surveyed. For example, 
Ireland had the 4th highest survival for cancer of the oesophagus out of 22 countries surveyed during the period 
2010-2014; Ireland ranked in the top half of countries surveyed for cancer of the oesophagus during the period 
2010-2014 and there was an improvement in survival rank  (↑) between the periods 2000-2004 and 2010-2014. 
Figures derived from Allemani et al (CONCORD-3, 2018) [2] 
 
 
 
 
 
 
 
 
How does cancer 
survival in Ireland 
compare with other 
countries? 
The CONCORD-3 project is a global international survey of 5-year cancer 
survival. A summary of trend in ranking for various cancers in Ireland 
relative to other EU countries is shown below for three diagnosis periods 
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TABLE 2-1  
ESTIMATED ANNUAL AVERAGE INCIDENCE, RATE AND CUMULATIVE RISK OF THE MOST COMMON CANCERS: 2018-2020‡ 
cancers       risk#1in_  risk# 1 in_   risk# 1 in_   risk# 1 in_   
Case count Rate*/100,00 to age 75 lifetime to age 75 lifetime 
ICD cancer site**  male   female   all   male   female  male male female female 
C00-96 all invasive cancers  20,184   16,723  36,907  725.6   562.2      
C00-43, C45-96 all invasive 
cancers excl. NMSC 
 13,152   11,641  24,793  477.8   399.1   3 (32.7%)   2 (51.3%)  4 (27.3%)  2 (45.3%)  
C00-D48 all registered tumours  22,809   21,944  44,753  819.1   757.1      
D00-48 non-invasive tumour  2,624   5,221  7,845  93.5   195.0  
    
C01-14 mouth & pharynx  372   160  532  14.0   5.7   84   60   220   156  
C15 oesophagus  345   171  516  12.5   5.2   123   68   327   127  
C16 stomach  361   209  570  12.7   6.6   119   51   229   101  
C18-20 colorectal cancer  1,633   1,186  2,819  58.3   38.3   26   13   41   18  
C22 liver   253   115  368  9.0   3.6   144   73   407   184  
C25 pancreas  314   303  617  11.0   9.3   135   61   168   66  
C33-34 lung and trachea  1,503   1,250  2,753  52.8   40.4   27   13   29   15  
C43 melanoma of skin  583   614  1,197  21.2   21.4   62   32   55   35  
C44 other skin  7,032   5,082  12,114  247.9   163.1   7   3   9   4  
C50 breast  37   3,667  3,704  1.3   132.8   1,002   529   11   7  
C53 cervix 
 
 302  302 
 
 11.5  
  
 132   112  
C54 corpus uteri 
 
 557  557 
 
 19.9  
  
 56   39  
C56 ovary 
 
 407  407 
 
 13.9  
  
 90   51  
C51-52, C55, C57-58 other 
malignant gynaecological 
 
 173  173 
 
 5.8  
  
264 133 
C61 prostate  3,890  
 
3,890  143.4  
 
 8   6  
  
C62 testis  173  
 
173  7.2  
 
 192   186  
  
C64 kidney  448   250  698  16.7   8.4   77   48   147   83  
C67 bladder  349   141  490  12.0   4.3  176 57 527 152 
C70-72, D32-33, D42-43 all brain 
& CNS 
 374   396  770  14.3   14.1   100   67   95   57  
C71-72 malignant brain & CNS  253   188  441  9.7   6.7   155   104   226   141  
C70-72 malignant meninges 
brain & CNS 
 256   199  455  9.8   7.1   153   103   222   136  
D32-33 benign brain & CNS  77   153  230  2.9   5.4   442   279   207   119  
D42-43 uncertain brain & CNS  41   43  84  1.6   1.7   626   500   731   491  
C73 thyroid gland  73   179  252  2.9   6.9   358   277   125   109  
C81 Hodgkin lymphoma  88   67  155  3.5   2.6   344   262   417   333  
C82-85 non-Hodgkin lymphoma  499   390  889  18.2   13.0   75   40   93   51  
C90 multiple myeloma  222   139  361  7.9   4.4   188   89   305   136  
C91-95 leukaemia  378   212  590  13.8   7.2   119   59   195   98  
 
‡ Average age-standardised rates for 2016-2018 period were projected onto populations for 2019-2020. 
Estimated average annual case counts and rates for 2018-2020 are presented in the table. 
* Rates are standardised to the 1976 European standard population; see Appendix II for rates standardised to the 2013 ESP. 
** Invasive cancer included all tumours classified as behaviour 3 in ICD-O-3 classification , including some neoplasms previously classified as uncertain behaviour, e.g. 
polycythaemia vera. 
# Cumulative risk of developing a type of cancer before age 75 and lifetime risk (adjusted for population mortality), expressed as a proportion, e.g. lifetime risk of 
developing an invasive cancer (other than NMSC) was approximately 1 in 2 in men (probability=51%) and 1 in 2 in women (probability=45%) (current probability 
method [3]. See Appendix V for further details.) 
† Vulva, vagina, uterus (NOS) and placenta. 
 
 
o Taking known cancer incidence rates during 2016-2018, and applying these rates to population estimates for 
2019-2020, an average of 44,753 cancers or other (non-invasive) tumours diagnosed annually was estimated 
for the period 2018-2020, representing an age-standardised incidence rate of 757 female cases and 819 
male cases per 100,000 per year (Table 2-1). 
2. CANCER INCIDENCE 2018-2020 
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o Approximately 18% of these were non-invasive tumours (in situ carcinomas, tumours of uncertain behaviour 
and benign brain and CNS tumours) and 27% were invasive non-melanoma skin cancers (NMSC, estimated 
12,114 cases per year) (Table 2-1). 
o Invasive cancers (incl. NMSC) were estimated to average 36,907 cases per year during 2018-2020, or an age-
standardised rate of 562 female and 726 male cases per 100,000 per year. 
o For all invasive cancers excluding NMSC, the figures most often quoted in international comparisons, an 
estimated 24,793 cases (13,152 males and 11,641 females) were diagnosed annually during 2018-2020, or 
55% of all invasive cases. 
o This is equivalent to an incidence rate of 399 cases per 100,000 females and 478 cases per 100,000 males per 
year — 22% higher for men than for women. 
o The annual average number of invasive cancers excluding NMSC during 2018-2020 was double the average 
during 1994-1996 (12,270 – 6,350 male and 5,920 female). 
o The cumulative risk (to age 75 years) of being diagnosed with an invasive cancer other than NMSC was 
approximately 1 in 3 in men and 1 in 4 for women 
o The cumulative lifetime risk of being diagnosed with an invasive cancer other than NMSC was approximately 
1 in 2 for both men and women. 
o There figures assume that average annual cancer incidence rates did not change between the period 2016-
2018 and 2019-2020, and that the Irish population estimates or projections available at the time of writing 
are accurate [4]. 
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FIGURE 2-1:  
ESTIMATED PERCENTAGES AND RANK OF THE MOST COMMONLY DIAGNOSED INVASIVE CANCER (EXCLUDING NMSC): 
ANNUAL AVERAGE 2018-2020 
males females all 
   
Low-incidence invasive cancers are not shown (c.10%), therefore percentages do not sum to 100% 
†Other gynaecological cancers: vulva, vagina, uterus (NOS) and placenta 
 
o If NMSC cases are excluded, prostate and female breast cancer were the most commonly diagnosed 
invasive cancers overall, each comprising almost one-third of all invasive cancers in men and women 
respectively, during the period 2018-2020 (Figure 2-1). 
o Colorectal cancer, lung cancer, melanoma of skin and non-Hodgkin lymphoma were the 2nd, 3rd, 4th and 
5th most common cancers in males respectively. 
o Lung cancer, colorectal cancer, melanoma of skin, and uterine cancer (corpus uteri) were the 2nd, 3rd, 4th 
and 5th most common cancers in females respectively.  
 
A more detailed breakdown of incidence statistics by cancer site is given in Appendix I & II. 
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o Of deaths occurring in 2017, 73.3% were attributed to 3 main chapters in the ICD-10 classification: IX (I00-
I99) diseases of the circulatory system (29.2%), II (C00-D48) neoplasms (30.8%), and X (J00-J99) diseases of 
the respiratory system (13.3%) [5].  
o An annual average of 9,063 deaths from invasive cancer (4,799 in males, 4,264 in females) occurred during 
the period 2015-2017, or 9,281 deaths from any neoplasm (Table 3-1). 
o This represents an estimated age-standardised mortality rate of 141 invasive cancer deaths per 100,000 
females and 186 deaths per 100,000 males per year (Table 3-1) — 32% higher for men than for women. 
The estimated cumulative risk (to age 75 year) of dying from invasive cancer was approximately 1 in 11 for 
women and 1 in 9 for men. 
 
TABLE 3-1:  
ANNUAL AVERAGE MORTALITY ATTRIBUTABLE TO CANCER: 2015-2017  
DEATHS Rate*/100,000 Risk # to age 75 
1 in: …  
male female all male female male female 
All neoplasms  4,918   4,363  9,281  190.8   143.7   9   10  
C00-96 all invasive cancers  4,799   4,264  9,063  186.2   140.9   9   11  
C01-14 mouth & pharynx  131   52  183  5.2   1.7   235   732  
C15 oesophagus  276   137  413  10.8   4.3   125   348  
C16 stomach  202   124  326  7.8   3.9   188   452  
C18-20 colorectum  598   412  1,010  23.2   13.1   70   120  
C22 liver  210   124  334  8.1   4.0   170   343  
C25 pancreas  276   253  529  10.7   8.2   133   173  
C33-34 lung and trachea  1,039   845  1,884  40.3   28.4   34   46  
C43 melanoma of skin  90   64  154  3.5   2.0   436   825  
C50 breast  5   719  724  0.2   24.9   4,193   56  
C53 cervix 
 
 84  84 
 
 3.2    411  
C54 corpus uteri 
 
 96  96 
 
 3.2    389  
C56 ovary 
 
 290  290 
 
 10.1    125  
C61 prostate  537  
 
537  20.5  
 
 128   
C62 testis  7  
 
7  0.3  
 
 5,282   
C64 kidney  143   73  216  5.6   2.3   249   672  
C67 bladder  155   67  222  5.9   2.0   411   968  
C71-72 brain & CNS  187   118  305  7.6   4.4   161   273  
C73 thyroid  13   17  30  0.5   0.6   1,987   2,549  
C81 Hodgkin lymphoma  14   8  22  0.6   0.3   2,212   5,328  
C82-85 non-Hodgkin lymphoma  157   125  282  6.0   3.8   274   435  
C90 multiple myeloma  95   77  172  3.6   2.4   468   733  
C91-95 leukaemia  155   102  257  6.0   3.2   285   491  
Source of data: Central Statistics Office, Ireland. 
*Rates are standardised to the 1976 European standard population.  
# Cumulative risk of dying of a cancer before age 75 using method as described in [6] expressed as a proportion, e.g. 1 in 10.  
See Appendix III for other cancers. 
 
3. CANCER MORTALITY 2015-2017 
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o Lung cancer was the leading cause of cancer death in both sexes, with an average of 1,884 deaths per year 
or 20% of cancer deaths in women and 22% of cancer deaths in men during the period 2015-2017 (Table 3-
1, Figure 3-1).  
o Colorectal cancer was the next most common cause of cancer death overall (but 3rd most common in 
females), with an average of 1,010 deaths per year or 10% of cancer deaths in females and 12% of cancer 
deaths in males. Deaths from lung, colorectal, breast and prostate cancers combined made up almost half 
(46%) of all deaths from cancer during this period. 
o Deaths from cancers of the oesophagus, pancreas and liver in males ranked 4th, 5th and 6th respectively, 
and comprised 16% of all cancer deaths in males. Mortality rankings for these high-fatality cancers were 
much higher than their incidence rankings (Figure 3-1). 
o Deaths from cancers of the ovary and pancreas ranked 4th and 5th respectively in female and comprised 
13% of cancer deaths in women, again much higher than the incidences ranking for these high fatality 
cancer (Fig. 3-1). A more detailed breakdown of mortality statistics is given in Appendix III. 
 
FIGURE 3-1: 
ESTIMATED PERCENTAGES AND RANK OF THE MOST COMMON CANCER DEATHS: ANNUAL AVERAGE 2015-2017 
males females all 
   
Cancers accounting for smaller percentages of cancer deaths (c.10% in total) are not shown, therefore percentages do not sum to 100%. 
Mortality data was provided by the Central Statistics Office (CSO). 
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Complete cancer prevalence is defined as the number of persons surviving with, or following a diagnosis of,  cancer in 
a given population at a particular point in time, the index date. For a cancer registry, fixed-duration prevalence is the 
number of cancer survivors calculated directly from observed data collected by the cancer registry since it was 
established.  
The NCRI began national collation of cancer registration in 1994 and it currently holds 25 years of complete or near-
complete incidence and follow-up information on cancer cases, up to the end of 2018. However, there remains a 
subset of cancer patients alive at the end of 2018 who are not included in NCRI data because they were diagnosed 
before 1994. The size of this hidden subset was estimated. The sum of the fixed-duration cancer survivor population 
(1994-2018) and estimated numbers of survivors from the hidden cancer subset (pre-1994) gives an estimate of 
complete prevalence, presented below (Table 4-1). 
 
TABLE 4-1. 
FIXED DURATION AND ESTIMATED COMPLETE PREVALENCE BY AGE AND SEX:  
NUMBER OF CANCER SURVIVORS* AT END OF 2018.  
sex age‡  Fixed duration 
(1994-2017)  
% %  Complete  
prevalence  
% % 
all  
 
 174,813  100.0% 100.0%  190,309  100.0% 100.0%  
<50  24,770  14.2% 
 
 25,387  13.3% 
 
 
50+  150,043  85.8% 
 
 164,922  86.7% 
 
        
males 
 
 86,013  100.0% 49.2%  91,263  100.0% 48.0%  
<50  9,654  11.2% 
 
 9,916  10.9% 
 
 
50+  76,359  88.8% 
 
 81,347  89.1% 
 
        
females 
 
 88,800  100.0% 50.8%  99,046  100.0% 52.0%  
<50  15,116  17.0% 
 
 15,471  15.6% 
 
 
50+  73,684  83.0% 
 
 83,575  84.4% 
 
 
*survivors of any invasive cancer other than non-melanoma skin cancer (ICD-10 C00-96 excluding C44);  
Only the first invasive cancer was counted per patient ignoring any subsequent cancers in other body 
sites. 
‡ Age category on 31/12/2018. 
 
o The figure reported for complete cancer prevalence (up to 31/12/2017) in last year’s annual report was 
180,550 [7]. For this report (up to 31/12/2018) the same figure was estimated at 190,309 (Table 4-1) which 
comprised c.3.9% of the Irish population in 2018.  
 
o These figures include patients still undergoing active treatment or palliative treatment at the end of 2018, in 
addition to longer-term survivors (either cured or potentially at risk of recurrence or relapse). 
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TABLE 4-2 
FIXED DURATION AND ESTIMATED COMPLETE PREVALENCE, BY CANCER TYPE:  
NUMBER OF CANCER SURVIVOR AT THE END OF 2018 
 
 Fixed duration 
(1994-2018)  
Complete  
to end of 2018 %*  
C50 breast             39,769               43,750  23.0% 
C61 prostate             39,165               39,705  20.9% 
C18-20 colorectum             21,035               22,738  11.9% 
C43 melanoma of skin             12,354               13,737  7.2% 
C82-85 non-Hodgkin lymphoma               7,451                 8,111  4.3% 
C33-34 lung               6,491                 6,608  3.5% 
C54 corpus uteri               5,368                 5,962  3.1% 
C91-95 leukaemia               5,102                 5,765  3.0% 
C64 kidney               5,116                 5,352  2.8% 
C62 testis               3,384                 4,863  2.6% 
C53 cervix               3,847                 4,738  2.5% 
C67 bladder               3,324                 4,384  2.3% 
C01-14 mouth & pharynx               3,148                 3,283  1.7% 
C73 thyroid               3,088                 3,227  1.7% 
C56 ovary               2,590                 3,187  1.7% 
C81 Hodgkin lymphoma               2,189                 2,925  1.5% 
C16 stomach               2,117                 2,227  1.2% 
C71-72 brain and spinal cord               1,697                 2,186  1.1% 
C90 multiple myeloma               1,856                 1,879  1.0% 
C15 oesophagus               1,375                 1,415  0.7% 
C51-52, C55, C57, C58 other gynaecological†                  989                 1,087  0.6% 
C25 pancreas                  837                    860  0.5% 
C22 liver                  709                    716  0.4% 
†Other gynaecological malignancies: vulva, vagina, uterus (NOS) and placenta 
*Percentage of all cancer survivors (complete prevalent cancers, C00-43, C45-96) 
 
The number of survivors of a given cancer type is related to its incidence rate, median age at diagnosis and survival 
prospects. Rare, high-fatality cancers diagnosed in elderly patients comprise only a small proportion of cancer 
survivors. Conversely, common cancers with good survival prospects diagnosed in younger persons will tend to 
predominate in the prevalent cancer population.  
Overall, the top most common cancers in the prevalent cancer population were: breast cancer (23% of all cancer 
survivors), prostate cancer (21%), colorectal cancer (12%) and skin melanoma (7%) (Table 4-2). These percentages are 
not mutually exclusive (i.e. they do not add up to 100% of the ‘all cancer’ set displayed in Table 4-1), as some cancer 
survivors had been diagnosed with more than one type of cancer. In some cases the patient’s first cancer may have 
been of a rarer type not listed in Table 4-2. 
Lung cancer, a common but high-fatality cancer accounted for only <4% of survivors, and less common, high-fatality 
cancers such as liver, pancreatic, oesophageal cancers and multiple myeloma comprised <3% of cancer survivors 
combined. 
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FIGURE 4-1 
ESTIMATED COMPLETE CANCER PREVALENCE IN IRELAND UP TO END OF 2018 
 
The numbers above the bars show the numbers living with a cancer diagnosis at the end of the year on the x-axis. Percentages represent 
the proportion of the Irish population living with a cancer diagnosis.  
Figures for 2018 are based on the latest available data at the time of writing this report, and projections are provided 
for years 2019 and 2020. 
 
For each year since the establishment of the cancer registry, the numbers of cancers diagnosed has increased due to 
growth of our population which increased by over 1 million between 1996 and 2016 [4]. Moreover, the proportion of 
the population most likely to be diagnosed with cancer (65+ years) expanded by over 50% over the same 20-year 
period. In combination with ongoing improvements in survival for most cancer types, this has resulted in a growing 
numbers of cancer survivors in the general population.  
In summary, it is estimated that there were over 190,000 cancer survivors at the end of 2018, and this number is likely 
to exceed 200,000 by the end of 2020 (Figure 4-1).  
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Ranked five-year and ten-year net survival for patients during 2012-2016 
Net survival estimates to five years and ten years post-diagnosis are presented here for cancer as a whole (excluding 
non-melanoma skin cancer) and for the most frequent cancers, based on follow-up of patients during 2012-2016 
(Figure 5-1). Net survival is calculated by comparing the observed survival of patients with the expected survival of 
persons of the same age and sex in the general population. It represents the cumulative probability of a patient 
surviving a given time in the hypothetical situation in which the disease of interest is the only possible cause of death, 
i.e. survival having controlled for other possible cause of death [8]. Actual (observed) survival will generally be lower 
than net survival, especially in older age-groups, reflecting deaths from other causes, although for high-fatality cancers 
and in younger age-groups most deaths among cancer patients will be related to the cancer. Site definitions (in terms 
of ICD-10 codes) are mainly those used in the EUROCARE international survival collaboration: for details, see 
https://www.ncri.ie/data/survival-statistics. 
All estimates are age-standardised i.e. survival for all ages 15-99 (15-64 for testicular cancer, 20-99 for bone cancer) 
was standardised to recommended population age weights [9]. The age-groups used differ for prostate cancer, and 
greater weighting is given to younger patients for some cancers (melanoma, bone, cervix, testis, brain and thyroid), 
reflecting difference in typical age at diagnosis for these cancers. Survival statistics for paediatric cases are not 
presented but were published by NCRI in 2017 [10].    
 Of the major cancers types (Figure 5-1), those with the highest average net survival were those of the testis (97% 
5-year/96% 10-year), prostate (92% 5-year/90% 10-year), and melanoma of skin (91% 5-year/88% 10-year). 
 Cancers with the lowest average net survival were those of the pancreas (10% 5-year/8% 10-year), liver (19% 5-
year/13% 10-year), and lung (20% 5-year/16% 10-year). 
 For all invasive cancers (excl. NMSC) during the period 2012-2016 (males and females combined), 5-year net 
survival reached 62% (Figure 5-1) representing an ongoing and substantial improvement compared with earlier 
periods: 1994-1999 (42%); 2005-2005 (51%); 2006-2010 (58%) [7]. 
 For all invasive cancers (excl. NMSC) during the period 2012-2016 (males), 5-year net survival reached 63% (Figure 
5-1): comparative earlier figures were 1994-1999 (39%); 2005-2005 (50%); 2006-2010 (58%) [7]. 
 For all invasive cancers (excl. NMSC) during the period 2012-2016 (females), 5-year net survival reached 61% 
(Figure 5-1): comparative earlier figures were 1994-1999 (46%); 2005-2005 (51%); 2006-2010 (57%) [7]. 
 For most individual cancer types, the annual report of 2019 [7] highlighted ongoing improvements in 5-year net 
survival from 1994-1999 up to 2011-2015. In this report, a summary of the recent CONCORD-3 results [2] is 
presented below. This section shows how cancer survival in Ireland has fared over time relative to other countries 
in the European Union (Figures 5-2 to 5-19).  
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FIGURE 5-1 
AGE-STANDARDIZED‡ ESTIMATES OF 5-YEAR AND 10-YEAR NET SURVIVAL  FOR INVASIVE CANCERS IN 
IRELAND: 2012-2016 
 
‘Hybrid’ estimates are presented above for the follow-up period 2012-2016 [11], representing one-year to five-year survival for cases 
diagnosed during 2011-2015 supplemented by longer-term follow-up of patients diagnosed pre-2011.  
‡Survival for all ages 15-99 is standardised to the standard populations recommended by Corazziari et al. (2004) [9]. 95% confidence 
intervals are shown. 
*Colon & colorectal cancer survival excludes carcinoids of the appendix. 
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International comparisons of cancer survival: CONCORD-3 project 
In this section, we present a selection of results from the most recent round of CONCORD global surveillance of 
cancer survival. The NCRI has contributed cancer survival data to this ongoing project since 1995.  5-year net survival 
is the parameter measured, which can inform on timely diagnosis and access to optimal treatment.  Most registries 
submitted data for patients diagnosed between 2000 and 2014, with follow-up to end of 2014. 
Survival trends were examined among patients diagnosed in three consecutive 5-year calendar periods. The ‘cohort’ 
approach was used to estimate survival for patients diagnosed during 2000-2004 and 2005-2009 and the ‘period’ 
approach for patients diagnosed during 2010-14. The ‘cohort’ approach is considered the gold standard [12] because 
it provides a survival estimate for a group of patients who were diagnosed during the same year or period, are likely 
to have been treated in similar fashion, and who have all been followed up for at least the duration of survival 
required, such as 5 years. This approach to the estimation of survival is easy to interpret, but other approaches are 
required when some patients have been followed up for less than 5 years. The ‘period’ approach [13] was used for 
patients diagnosed during 2010-14 because 5 years of follow-up data were not available for all patients. This 
combination of ‘cohort’ and ‘period’ approaches facilitates monitoring of cancer survival trends over an extended 
time span, from the earliest to the most recent years of cancer registration for which follow-up data are available 
[14]. 
The CONCORD-3 project calculated ‘net survival’, the cumulative probability of surviving up to a given time since 
diagnosis (5 years) after correcting for other causes of death (background mortality), as also reported in NCRI’s own 
survival statistics. To control for the wide differences in background mortality between participating jurisdictions and 
to allow comparisons over time and between countries, the CONCORD-3 researchers compiled life tables of all-cause 
mortality for each calendar year during 2000-2014 for the general population of each country.  
The 18 cancers surveyed were: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, 
ovary, prostate, and melanoma of the skin in adults, together with brain tumours, leukaemias, and lymphomas in 
both adults and children. The selection criteria and description of these cancers is presented in Table 5-1. While 
CONCORD-3 is a global project involving 67 countries, only the results for the EU28 member states (as of 2018) are 
presented below [2].  
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Table 5-1 
CONCORD-3: definition of selected malignancies (ICD-O-3) 
 Topography or morphology codes  [15] Description 
Oesophagus C15.0–C15.5, C15.8–C15.9 Oesophagus 
Stomach C16.0–C16.6, C16.8–C16.9 Stomach 
Colon C18.0–C18.9, C19.9 Colon and rectosigmoid 
junction 
Rectum C20.9, C21.0–C21.2, C21.8 Rectum, anus, and anal 
canal 
Liver C22.0–C22.1 Liver and intrahepatic 
bile ducts 
Pancreas C25.0–C25.4, C25.7–C25.9 Pancreas 
lung C34.0–C34.3, C34.8–C34.9 Lung and bronchus 
Melanoma of 
skin 
8720–8790 provided topography was C44.0–C44.9, C51.0, C51.9, C60.9, 
or C63.2 
Melanoma of the skin, including skin of labia majora, vulva, 
penis, and scrotum 
Breast (female) C50.0–C50.6, C50.8–C50.9 Breast 
Cervix C53.0–C53.1, C53.8–C53.9 Cervix uteri 
Ovary C48.0–C48.2, C56.9, C57.0–C57.4, C57.7–C57.9 Ovary, fallopian tube and uterine ligaments, other and 
unspecified female genital organs, peritoneum, and 
retroperitoneum 
Prostate C61.9 Prostate gland 
Brain (adults) C71.0–C71.9 Brain (adults) 
Myeloid 
(adults) 
9740, 9741, 9742, 9800, 9801, 9805, 9806,9807, 9808, 9809, 9840, 9860, 
9861, 9863,9865, 9866, 9867, 9869, 9870, 9871, 9872, 9873, 9874, 9875, 
9876, 9891, 9895, 9896, 9897, 9898, 9910, 9911, 9920, 9930, 9931, 
9945, 9946, 9950, 9960, 9961, 9962, 9963, 9964, 9975, 9980, 9982, 
9983, 9984, 9985, 9986, 9987, 9989, 9991, 9992 
All myeloid malignancies 
HAEMACARE groups 20-25 [16] 
Lymphoid 
(adults) 
9590, 9591, 9596, 9597, 9650–9655, 9659, 9661–9665, 9667, 9670, 
9671, 9673, 9675, 9678, 9679, 9680, 9684, 9687–9691, 9695, 9698, 
9699, 9700–9702, 9705, 9708, 9709, 9712, 9714, 9716–9719, 9725–
9729, 9731–9735, 9737, 9738, 9760–9762, 9764, 9811–9818, 9820, 
9823, 9826, 9827,9831–9837, 9940, 9948 
All lymphoid malignancies, HAEMACARE groups 1–19 
Brain (children) C71.0–C71.9 Brain (children) 
Acute 
lymphoblastic 
leukaemia 
(children) 
 
9835–9837; plus 9811–9818 provided 
topography was C42.0, C42.1, C42.3, C42.4 or C80.9 
Precursor-cell acute lymphoblastic leukaemia, The 
International Classification of Childhood 
Cancer (3rd ed.) [17] incorporating morphology codes from 
the first revision of ICD-O-3 was used to define childhood 
acute lymphoblastic leukaemia (group Ia1)  
Lymphoma 
(children) 
 
9590, 9591, 9596, 9597, 9650–9655, 9659, 9661–9665, 9667, 9670, 
9671, 9673,9675, 9678–9680, 9684, 9687–9691, 9695, 9698–9702, 9705, 
9708, 9709, 9712, 9714,9716–9719, 9725–9729, 9731–9735, 9737, 9738, 
9740–9742, 9750–9762, 9764–9769, 9970, 9971; plus 9811–9818 
provided topography was 
not C42.0, C42.1, C42.3, C42.4, or C80.9 
All lymphomas, The International Classification of Childhood 
Cancer (3rd ed.) [17] Incorporating morphology codes from 
the first revision of ICD-O-3 was used to define lymphoma in 
children (group II). 
CONCORD-3: Allemani et al, 2018 [2] 
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FIGURE 5-2 
CANCER OF THE OESOPHAGUS: EU-28: 5-YEAR NET SURVIVAL (%) AND RANK: 2010-2014 
 
Excluding Bulgaria, Greece , Romania, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for oesophageal cancer ranged from 5% to 24% during the period 2010-2014 among 22 EU countries 
surveyed. Net survival in Ireland, increased from 13% (2000-2004) to 17% (2005-2009) to 20% during the period 2010-
2014. Ireland ranked 4th of 22 EU countries surveyed for the period 2010-2014.  
 
 
FIGURE 5-3 
CANCER OF THE STOMACH: EU-28: 5-YEAR NET SURVIVAL (%) AND RANK: 2010-2014 
 
Excluding  Greece , Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for stomach cancer ranged from 16% to 38% during the period 2010-2014 among 24 EU countries 
surveyed. Net survival in Ireland, increased from 19% (2000-2004) to 22% (2005-2009) to 28% during the period 2010-
2014. Ireland ranked 9th of 24 EU countries surveyed for the period 2010-2014.   
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FIGURE 5-4 
CANCER OF THE COLON : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the colon ranged from 51% to 68% during the period 2010-2014 among 24 EU 
countries surveyed. Net survival in Ireland, increased from 53% (2000-2004) to 58% (2005-2009) to 61% during the 
period 2010-2014. Ireland ranked 13th of 24 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-5 
CANCER OF THE  RECTUM : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding , Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the rectum ranged from 46% to 67% during the period 2010-2014 among 24 EU 
countries surveyed. Net survival in Ireland, increased from 51% (2000-2004) to 57% (2005-2009) to 62% during the 
period 2010-2014. Ireland ranked 9th of 24 EU countries surveyed for the period 2010-2014.  
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FIGURE 5-6 
CANCER OF THE LIVER: EU-28: 5-YEAR NET SURVIVAL  AND RANK (%): 2010-2014 
 
Excluding, Greece , Romania, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the liver ranged from 4% to 21% during the period 2010-2014 among 23 EU countries 
surveyed. Net survival in Ireland, ranged from 12% (2000-2004) to 12% (2005-2009) to 14% during the period 2010-
2014. Ireland ranked 9th of 23 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-7 
CANCER OF THE PANCREAS: EU-28: 5-YEAR NET SURVIVAL (%): 2010-2014 
 
Excluding Greece, Bulgaria, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the pancreas ranged from 6% to 14% during the period 2010-2014 among 23 EU 
countries surveyed. Net survival in Ireland, increased from 6% (2000-2004) to 7% (2005-2009) to 10% during the period 
2010-2014. Ireland ranked 8th of 23 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-8 
CANCER OF THE LUNG: EU-28: 5-YEAR NET SURVIVAL (%): 2010-2014 
 
Excluding Greece, Bulgaria, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the lung ranged from 10% to 20% during the period 2010-2014 among 23 EU countries 
surveyed. Net survival in Ireland, increased from 10% (2000-2004) to 14% (2005-2009) to 18% during the period 2010-
2014. Ireland ranked 6th of 23 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-9 
MELANOMA OF THE SKIN: EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece , Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for melanoma ranged from 61% to 93% during the period 2010-2014 among 24 EU countries 
surveyed. Net survival in Ireland, increased from 86% (2000-2004) to 87% (2005-2009) to 89% during the period 2010-
2014. Ireland ranked 8th of 24 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-10 
CANCER OF THE BREAST (FEMALES): EU-28: 5-YEAR NET SURVIVAL (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for breast cancer ranged from 74% to 89% during the period 2010-2014 among 24 EU countries 
surveyed. Net survival in Ireland, increased from 77% (2000-2004) to 81% (2005-2009) to 82% during the period 2010-
2014. Ireland ranked 16th of 24 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-11 
CANCER OF THE CERVIX: EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the cervix ranged from 55% to 70% during the period 2010-2014 among 24 EU 
countries surveyed. Net survival in Ireland, increased from 58% (2000-2004) to 59% (2005-2009) to 64% during the 
period 2010-2014. Ireland ranked 16th of 24 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-12 
CANCER OF THE OVARY: EU-28: 5-YEAR NET SURVIVAL (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the ovary ranged from 28% to 47% during the period 2010-2014 among 24 EU 
countries surveyed. Net survival in Ireland, increased from 29% (2000-2004) to 31% (2005-2009) to 33% during the 
period 2010-2014. Ireland ranked 23rd of 24 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-13 
CANCER OF THE PROSTATE: EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for prostate cancer ranged from 68% to 94% during the period 2010-2014 among 24 EU countries 
surveyed. Net survival in Ireland, increased from 84% (2000-2004) to 90% (2005-2009) to 91% during the period 2010-
2014. Ireland ranked 6th of 24 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-14 
CANCER OF THE BRAIN (ADULTS) : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Bulgaria, Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the brain (adults) ranged from 21% to 42% during the period 2010-2014 among 23 EU 
countries surveyed. Net survival in Ireland, increased from 27% (2000-2004) to 31% (2005-2009) to 35% during the 
period 2010-2014. Ireland ranked 4th of 23 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-15 
CANCER OF THE BRAIN (CHILDREN)  : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Austria, Bulgaria, Luxembourg, Cyprus, Malta and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for cancer of the brain (children) ranged from 60% to 81% during the period 2010-2014 among 21 
EU countries surveyed. Net survival in Ireland, increased from 68% (2000-2004) to 69% (2005-2009) to 74% during the 
period 2010-2014. Ireland ranked 7th of 21 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-16 
LYMPHOID TUMOURS (ADULTS) : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for lymphoid tumours in adults ranged from 40% to 72% during the period 2010-2014 among 24 
EU countries surveyed. Net survival in Ireland, increased from 55% (2000-2004) to 64% (2005-2009) to 67% during the 
period 2010-2014. Ireland ranked 6th of 24 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-17 
MYELOID TUMOURS (ADULTS) : EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Greece, Luxembourg, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for myeloid tumours in adults ranged from 21% to 58% during the period 2010-2014 among 24 EU 
countries surveyed. Net survival in Ireland, ranged from 48% (2000-2004) to 53% (2005-2009) to 53% during the period 
2010-2014. Ireland ranked 5th of 24 EU countries surveyed for the period 2010-2014. 
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FIGURE 5-18 
ACUTE LYMPHOBLASTIC LEUKAEMIA (CHILDREN) : EU-28: 5-YEAR NET SURVIVAL (%): 2010-2014 
 
Excluding Austria, Luxembourg, Malta, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for acute lymphoblastic leukaemia in children ranged from 54% to 95% during the period 2010-
2014 among 23 EU countries surveyed. Net survival in Ireland, increased from 83% (2000-2004) to 87% (2005-2009) 
to 88% during the period 2010-2014. Ireland ranked 10th of 23 EU countries surveyed for the period 2010-2014. 
 
FIGURE 5-19 
LYMPHOMA (CHILDREN): EU-28: 5-YEAR NET SURVIVAL AND RANK (%): 2010-2014 
 
Excluding Austria , Latvia, Romania, Luxembourg, Malta, Cyprus and Hungary; data from Allemani et al. 2018 [2] 
 
5-year net survival for lymphoma in children ranged from 88% to 100% during the period 2010-2014 among 21 EU 
countries surveyed. Net survival in Ireland, ranged from 97% (2000-2004) to 96% (2005-2009) to 95% during the period 
2010-2014. Ireland ranked 4th of 21 EU countries surveyed for the period 2010-2014. 
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Trend in Ireland’s cancer survival relative to other countries in the EU  
TABLE  5-2 
IRELAND’S RANK WITHIN THE EUROPEAN UNION FOR 5-YEAR NET SURVIVAL: 
BY CANCER TYPE AND PERIOD 
 2000-2004 2005-2009 2010-2014 top half 
2010-2014? 
rank comparison 
2010-2014 vs.  
2000-2004 
oesophagus 5 of 22 3 of 23 4 of 22 yes ↑ 
stomach 19 of 23 16 of 24 9 of 24 yes ↑ 
rectum 14 of 23 13 of 24 9 of 24 yes ↑ 
pancreas 12 of 22 12 of 23 8 of 23 yes ↑ 
lung 15 of 23 12 of 24 6 of 24 yes ↑ 
melanoma skin 9 of 23 10 of 24 8 of 24 yes ↑ 
cervix 18 of 23 21 of 24 16 of 24  ↑ 
prostate 10 of 23 10 of 24 6 of 24 yes ↑ 
brain-adults 6 of 22 5 of 23 4 of 23 yes ↑ 
brain-children 11 of 21 12 of 20 7 of 22 yes ↑ 
lymphoid-adults 11 of 23 6 of 24 6 of 24 yes ↑ 
Acute lymphoblastic leukaemia -
children 
11 of 23 11 of 23 10 of 23 yes ↑ 
colon 13 of 23 11 of 24 13 of 24  ↔ 
breast 16 of 23 15 of 24 16 of 24  ↔ 
ovary 23 of 23 22 of 24 23 of 24  ↔ 
liver 8 of 23 10 of 23 9 of 23 yes ↓ 
myeloid-adults 3 of 23 4 of 24 5 of 24 yes ↓ 
lymphoma-children 1 of 21 2 of 21 4 of 21 yes ↓ 
Data derived from CONCORD-3, Allemani et al. 2018 [2] 
The figures in the table show Ireland’s survival rank within number of EU28 countries surveyed.  
For example, Ireland had the 4th highest survival for cancer of the oesophagus out of 22 countries surveyed during the period 2010-2014; 
Ireland ranked in the top half of countries surveyed for cancer of the oesophagus during 2010-2014 and there was an improvement in 
survival rank  (↑) between the periods 2000-2004 and 2010-2014 
 
 Of the 18 cancer types considered for five-year survival during the period 2010-2014, Ireland was placed in 
the top half of countries surveyed for 14 of these cancers. For the period 2010-2014, Ireland’s ranking 
among EU countries was highest for cancers of the oesophagus (4th), pancreas (8th), lung (6th), melanoma 
skin (8th), prostate (6th), brain (adults 4th and children 7th), myeloid and lymphoid cancers in adults (5th and 6th 
respectively) and lymphoma in children (4th).   
 
 Ireland ranked in the lower half of countries surveyed for cancer of the cervix (64%, 16th of 24), but of the 
other countries, only three countries approached 70% survival (Denmark 70%, Sweden 68% and the 
Netherlands 68%) and five countries had survival below 60%.  
 
 Ireland also ranked in the lower half of countries for cancer of the colon (61%, 13th of 24) where only 4 
countries exceeded 65%. It is anticipated that Ireland should fare better in the future for colon cancer 
survival once the effect of bowel screening is fully realised after implementation in 2015. 
 
 Ireland ranked in the lower half of countries surveyed for breast cancer (82%, 16th of 24 countries), but 7 
countries showed survival below 80% and only three countries showed survival above 88%.  
 
 Ireland’s survival ranking for ovarian cancer was poor (33%, 23rd of 24 countries surveyed) where the best EU 
country was Sweden (47%).   
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3-year annual average 2015-2017 and estimates for 2018-2020 
 
2015-2017 2018-2020 (estimate)‡ 
cancer  male  female  all   male  female  all  
C00-96 all invasive cancers*                  18,205          15,256  33,461           20,184          16,723  36,907 
C00-43, C45-96 all invasive cancers excl. NMSC                  11,926          10,624  22,550           13,152          11,641  24,793 
C00-96, D00-D48 all registered tumours                  20,393          20,891  41,284           22,809          21,944  44,753 
D00-48 non-invasive tumours**                    2,188            5,635  7,823             2,624            5,221  7,845 
C00 lip                         18                   3  21                  17                   5  22 
C01 base of tongue                         35                   9  44                  35                 11  46 
C02 other and unspecified parts of tongue                         51                 29  80                  68                 29  97 
C03 gum                         10                 13  23                  13                   8  21 
C04 floor of mouth                         32                   7  39                  29                 11  40 
C05 palate                         15                   8  23                  18                   9  27 
C06 other and unspecified parts of mouth                         19                 13  32                  22                 20  42 
C07 parotid gland                         28                 14  42                  32                 15  47 
C08 other and unspecified major salivary glands                           7                   2  9                    7                   4  11 
C09 tonsil                         58                 24  82                  64                 26  90 
C10 oropharynx***                         25                   3  28                  23                   6  29 
C11 nasopharynx                         16                   7  23                  14                   6  20 
C12 pyriform sinus                         19                   4  23                  18                   4  22 
C13 hypopharynx                         19                   5  24                  23                   7  30 
C14 other and ill-defined sites in the lip, oral cavity and pharynx                           4                   2  6                    7                   4  11 
C01-14 mouth & pharynx                       337               140  477                372               160  532 
C00-14 lip oral cavity and pharynx                       354               144  498                389               165  554 
C15 oesophagus                       299               145  444                345               171  516 
C16 stomach                       363               189  552                361               209  570 
C17 small intestine                         55                 46  101                  71                 56  127 
C18 colon                       983               796  1,779             1,038               853  1,891 
C19 rectosigmoid junction                       109                 69  178                108                 79  187 
C20 rectum                       461               231  692                487               253  740 
C21 anus                         26                 35  61                  30                 48  78 
C19-20 rectosigmoid junction and rectum                       571               300  871                595               333  928 
C19-21 rectum and anus                       597               335  932                624               381  1,005 
C18-20 colorectum                    1,554            1,096  2,650             1,633            1,186  2,819 
C18-21 colorectum and anus                    1,580            1,131  2,711             1,662            1,234  2,896 
C17-21 intestine                    1,635            1,177  2,812             1,733            1,290  3,023 
C22 liver and intrahepatic bile ducts                       212                 95  307                253               115  368 
C23 gallbladder                         18                 50  68                  18                 50  68 
C24 other and unspecified parts of biliary tract                         76                 64  140                  89                 70  159 
C23-24 gallbladder and biliary tract                         94               114  208                108               121  229 
C22-24 liver gall bladder and biliary                       306               209  515                361               236  597 
C25 pancreas                       298               265  563                314               303  617 
C26 other and ill-defined digestive organs                         33                 33  66                  42                 40  82 
C30 nasal cavity and middle ear                           7                   6  13                    6                   7  13 
C31 accessory sinuses                         10                   6  16                  11                   8  19 
C32 larynx                       146                 33  179                156                 34  190 
C00-14, C30-32 all head and neck                       518               189  707                562               214  776 
C00-15, C32 lip oral pharynx larynx oesophagus                       799               321  1,120                890               370  1,260 
C33 trachea                           1                   1  2                    0                   1  1 
C34 bronchus and lung                    1,392            1,196  2,588             1,502            1,248  2,750 
C33-34 lung and trachea                    1,392            1,197  2,589             1,503            1,250  2,753 
C37 thymus                           5                   4  9                    4                   4  8 
C38 heart, mediastinum and pleura                           9                   5  14                  13                   5  18 
C39 other and ill-defined respiratory and intrathoracic                           0                  0   0                    1                  0   1 
C40 bone and articular cartilage of limbs                         13                 10  23                  16                 10  26 
C41 bone and articular cartilage of other and unspecified                         16                 11  27                  23                 11  34 
C40-41 bone and articular and unspecified                         13                 10  23                  16                 10  26 
C43 melanoma of skin                       544               587  1,131                583               614  1,197 
C44 other skin                    6,279            4,632  10,911             7,032            5,082  12,114 
C45 mesothelioma                         44                   9  53                  39                   8  47 
C46 Kaposi sarcoma                           6                   0  6                    9                   0  9 
C47 peripheral nerves and autonomic nervous system                           2                   3  5                    4                   5  9 
C48 retroperitoneum and peritoneum                           8                 18  26                  10                 21  31 
C49 other connective and soft tissue                         93                 56  149                121                 69  190 
C50 breast                         29            3,256  3,285                  37            3,667  3,704 
C51 vulva 
 
               61  61 
 
               67  67 
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3-year annual average 2015-2017 and estimates for 2018-2020 
 
2015-2017 2018-2020 (estimate)‡ 
cancer  male  female  all   male  female  all  
C52 vagina 
 
                 9  9 
 
               17  17 
C53 cervix uteri 
 
             275  275 
 
             302  302 
C54 corpus uteri 
 
             512  512 
 
             557  557 
C55 uterus, part unspecified 
 
               28  28 
 
               31  31 
C56 ovary 
 
             400  400 
 
             407  407 
C57 other and unspecified female genital organs 
 
               49  49 
 
               56  56 
C58 placenta 
 
                 1  1 
 
                 2  2 
C51-52, C55, C57-58 other malignant gynaecological neoplasms 
 
             148  148 
 
             173  173 
C60 penis                         38  
 
38                  46  
 
46 
C61 prostate                    3,447  
 
3,447             3,890  
 
3,890 
C62 testis                       175  
 
175                173  
 
173 
C63 other and unspecified male genital organs                           4  
 
4                    4  
 
4 
C64 kidney, except renal pelvis                       419               235  654                448               250  698 
C65 renal pelvis                         16                   8  24                  15                 12  27 
C66 ureter                         19                   9  28                  23                 10  33 
C64-66 kidney incl. renal pelvis and ureter                       454               252  706                486               272  758 
C67 bladder                       294               111  405                349               141  490 
C68 other and unspecified urinary organs                           5                   4  9                  12                   5  17 
C69 eye and adnexa                         34                 28  62                  34                 29  63 
C70 meninges                           3                   5  8                    3                 11  14 
C71 brain                       216               144  360                244               175  419 
C72 spinal cord, cranial nerves and other parts of CNS                           6                   7  13                    9                 13  22 
C71-72 brain and spinal cord                       222               151  373                253               188  441 
C70-72 malignant meninges brain and spinal cord                       225               157  382                256               199  455 
C70-72, D32-33, D42-43 all meninges brain and CNS                       327               360  687                374               396  770 
C73 thyroid gland                         68               185  253                  73               179  252 
C74 adrenal gland                           9                 10  19                    9                   7  16 
C75 other endocrine glands and related structures                           8                   5  13                  12                 10  22 
C76 other and ill-defined sites                         12                 22  34                  21                 25  46 
C77 secondary and unspecified lymph nodes                           4                   3  7                    9                   8  17 
C80 neoplasm without specification of site                       192               181  373                260               215  475 
C81 Hodgkin lymphoma                         89                 68  157                  88                 67  155 
C82 follicular nodular non-Hodgkin lymphoma                       103               111  214                107               101  208 
C83 diffuse non-Hodgkin lymphoma                       237               166  403                238               174  412 
C84 peripheral and cutaneous T-cell lymphomas                         38                 26  64                  47                 27  74 
C85 other and unspecified types of non-Hodgkin lymphoma                         85                 62  147                107                 88  195 
C82-85 all non-Hodgkin lymphoma                       463               365  828                499               390  889 
C81-85 lymphoma (total)                       552               433  985                587               458  1,045 
C88 immunoproliferative diseases                         11                   7  18                  15                   5  20 
C90 multiple myeloma                       205               143  348                222               139  361 
C88-90 multiple myeloma and immunoproliferative                       216               150  366                237               144  381 
C911 leukaemia CLL                       158                 80  238                153                 74  227 
C91 lymphoid leukaemia                       209               113  322                217               107  324 
C92 myeloid leukaemia                       114                 88  202                127                 81  208 
C93 monocytic leukaemia                           4                   2  6                    2                   2  4 
C94 other leukaemia of specified cell type                           5                   1  6                    5                   2  7 
C95 leukaemia of unspecified cell type                         17                 14  31                  27                 19  46 
C91-95 leukaemia (total)                       349               219  568                378               212  590 
C96 other and unspecified lymphoid haematopoietic                       224               169  393                232               172  404 
D00 carcinoma in situ of oral cavity, oesophagus and stomach                         17                 13  30                  17                 15  32 
D01 carcinoma in situ of other and unspecified digestive organs                         10                 10  20                  16                 12  28 
D02 carcinoma in situ of middle ear and respiratory system                         19                   8  27                  25                 13  38 
D03 melanoma in situ                       341               351  692                456               455  911 
D04 carcinoma in situ of skin                       999            1,215  2,214             1,214            1,366  2,580 
D05 carcinoma in situ of breast                           2               370  372                    2               436  438 
D06 carcinoma in situ of cervix uteri 
 
          2,952  2,952 
 
          2,190  2,190 
D07 carcinoma in situ of other and unspecified genital organs                       102                 62  164                101                 58  159 
D09 carcinoma in situ of other and unspecified sites                         81                 20  101                100                 31  131 
D32 benign meninges                         46               141  187                  48               127  175 
D33 benign brain and other parts of CNS                         20                 25  45                  29                 27  56 
D32-33 benign meninges, brain & CNS                         66               166  232                  77               153  230 
D35 benign other and unspecified endocrine glands [intracranial only]                         62                 50  112                  54                 42  96 
D37 uncertain or unknown of oral cavity and digestive organs                         33                 44  77                  42                 48  90 
D38 uncertain or unknown of middle ear and respiratory intrathoracic                           6                   5  11                    7                   5  12 
D39 uncertain or unknown of female genital organs 
 
               93  93 
 
               95  95 
D40 uncertain or unknown of male genital organs                           3  
 
3                    3  
 
3 
D41 uncertain or unknown of urinary organs                       240                 99  339                271                 97  368 
D42 uncertain or unknown of meninges                           8                 11  19                    9                 14  23 
D43 uncertain or unknown of brain and CNS                         27                 26  53                  31                 30  61 
D42-43 uncertain meninges, brain & CNS                         36                 37  73                  41                 43  84 
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3-year annual average 2015-2017 and estimates for 2018-2020 
 
2015-2017 2018-2020 (estimate)‡ 
cancer  male  female  all   male  female  all  
D44 uncertain or unknown of endocrine glands                         12                 16  28                  15                 24  39 
D47 other uncertain or unknown of lymphoid and haematopoietic                         77                 68  145                  76                 62  138 
D48 uncertain or unknown of other and unspecified sites                         81                 53  134                106                 73  179 
HAEMACARE classification of tumours of lymphatic and haematopoietic tissue       
H01 Lymphoma NOS                         26                 23  49                  35                 35  70 
H02 NH lymphoma NOS                         57                 37  94                  69                 50  119 
H03 Composite Hodgkin and Non-Hodgkin                           0                  0    0                    1                   1  2 
H04 Hodgkin lymphoma nodular lymphocyte predominance                           7                   3  10                    7                   3  10 
H05 Classical HL                         82                 65  147                  81                 65  146 
H06 Chronic lymphocytic leukaemia/Small lymphocytic lymphoma                       172                 89  261                167                 80  247 
H07 Immunoproliferative diseases                         18                 11  29                  21                   9  30 
H08 Mantle cell/centrocytic lymphoma                         28                   9  37                  31                 10  41 
H09 Follicular B lymphoma                         85                 89  174                  88                 82  170 
H10 Diffuse B lymphoma                       173               136  309                174               149  323 
H11 Burkitt lymphoma                         12                   6  18                  12                   3  15 
H12 Marginal zone lymphoma                         20                 25  45                  21                 22  43 
H13 T lymphoma cutaneous                         15                 10  25                  20                 12  32 
H14 Other T cell lymphomas                         26                 18  44                  32                 19  51 
H15 Lymphoblastic lymphoma,/Acute precursor cell lymphatic lymphoma                         36                 28  64                  44                 27  71 
H16 Plasma cell neoplasms                       208               143  351                223               140  363 
H18 Mature B cell leukaemia hairy cell                         12                   2  14                  15                   3  18 
H19 Lymphatic leukaemia NOS                           1                   1  2                    0                   1  1 
H20 Leukaemia NOS                         17                 14  31                  27                 19  46 
H21 Myeloid leukaemia NOS                           2                   1  3                    3                   2  5 
H22 Acute myeloid leukaemia                         85                 66  151                  98                 62  160 
H23 Myeloproliferative neoplasms                       127               115  242                149               122  271 
H24 Myelodysplastic syndrome                       105                 65  170                  95                 58  153 
H25 Myelodysplastic, Myeloproliferative neoplasm                         22                   9  31                  20                   8  28 
C00-96 all cancers excl. NMSC & lung                  10,534            9,427  19,961           11,650          10,391  22,041 
C00-96 all cancers excl. NMSC & prostate                    8,479          10,624  19,103             9,262          11,641  20,903 
C00-96 all cancers excl. NMSC & breast                  11,897            7,368  19,265           13,115            7,973  21,088 
C00-96 all cancers excl. NMSC & breast & prostate                    8,450            7,368  15,818             9,225            7,973  17,198 
C91-95 leukaemia (total) excl. C911 leukaemia CLL                       192               139  331                225               138  363 
 
*Incidence figures for C00-C96 where C96 presented in this report include polycythaemia vera, myelodysplastic syndromes and chronic 
myeloproliferative disease, considered malignant in ICDO3 but previously classed as uncertain behaviour (and previously coded under ICD10 
codes D45-D47).  
** D00-D48 tumours in this report exclude polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease (see note 
above). 
*** The ICD-10 definition C10 “Malignant neoplasm of oropharynx” is not equivalent to (and is narrower than) the definition of 
“oropharyngeal” used to categorise sites/subsites for purposes of identifying cancers where HPV-associated cancers may be involved. The 
broader, HPV-relevant definition includes the whole of C01 (base of tongue), C09 (tonsil) and C10 (oropharynx sensu stricto) and selected 
subsites within C02 (other/unspecified parts of tongue), C05 (palate) and C14 (other/ill-defined sites of lip, oral cavity & pharynx), further 
characterized by cell-type (squamous cell carcinoma). 
‡ Average age-specific rates for 2016-2018 were calculated and applied to population estimates for 2019 and 2020 to allow estimation of 
average annual counts for 2018-2020 presented in the table. Of the estimated average annual counts for 2018-2020, counts for the year 2018 
were observed, not estimated. 
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Age-standardised rate (ASR, per 100,000): annual average for 2018-2020 (assumed to be unchanged from 2016-2018). Incidence 
rate was calculated using two different age weights: 1976 and 2013 European standard populations (ESP) [18].  
 
Age-standardised rate (ASR) per 100,000 (estimate)       
Estimated 3-year annual average: 2018-2020 ESP 1976  ESP 2013  
cancer  male   female   all   male   female  all  
C00-96 all invasive cancers                       725.6            562.2     637.9               1,127.9            814.2       957.5  
C00-43, C45-96 all invasive cancers excl. NMSC                       477.8            399.1     435.6                  721.6            560.8       634.9  
C00-96, D00-D48 all registered tumours                       819.1            757.1     782.6               1,276.0         1,047.6    1,148.1  
D00-48 non-invasive tumours                         93.5            195.0     144.7                  148.0            233.5       190.6  
C00 lip                           0.6                0.2         0.4                      0.9                0.3           0.6  
C01 base of tongue                           1.3                0.4         0.9                      1.8                0.5           1.1  
C02 other and unspecified parts of tongue                           2.6                1.0         1.8                      3.5                1.4           2.4  
C03 gum                           0.5                0.3         0.3                      0.8                0.4           0.6  
C04 floor of mouth                           1.1                0.4         0.7                      1.4                0.5           1.0  
C05 palate                           0.7                0.3         0.5                      0.9                0.4           0.7  
C06 other and unspecified parts of mouth                           0.8                0.7         0.8                      1.2                1.0           1.1  
C07 parotid gland                           1.1                0.5         0.8                      2.1                0.7           1.3  
C08 other and unspecified major salivary glands                           0.3                0.1         0.2                      0.4                0.2           0.3  
C09 tonsil                           2.5                1.0         1.8                      3.1                1.2           2.1  
C10 oropharynx                           0.9                0.2         0.5                      1.1                0.3           0.7  
C11 nasopharynx                           0.5                0.2         0.4                      0.7                0.3           0.5  
C12 pyriform sinus                           0.7                0.1         0.4                      0.9                0.2           0.6  
C13 hypopharynx                           0.8                0.2         0.5                      1.2                0.4           0.8  
C14 other and ill-defined sites in the lip, oral cavity and pharynx                           0.3                0.1         0.2                      0.4                0.2           0.3  
C01-14 mouth & pharynx                         14.0                5.7         9.7                    19.4                7.6         13.2  
C00-14 lip oral cavity and pharynx                         14.6                5.9       10.1                    20.3                7.9         13.8  
C15 oesophagus                         12.5                5.2         8.7                    19.3                8.8         13.8  
C16 stomach                         12.7                6.6         9.4                    20.8              10.6         15.3  
C17 small intestine                           2.6                1.8         2.2                      3.9                2.8           3.3  
C18 colon                         36.7              27.1       31.6                    59.9              42.6         50.5  
C19 rectosigmoid junction                           3.9                2.6         3.2                      5.9                3.9           4.9  
C20 rectum                         17.7                8.6       12.9                    26.7              12.3         19.1  
C21 anus                           1.1                1.7         1.4                      1.6                2.3           1.9  
C19-20 rectosigmoid junction and rectum                         21.6              11.3       16.2                    32.6              16.3         24.0  
C19-21 rectum and anus                         22.7              13.0       17.6                    34.2              18.5         25.9  
C18-20 colorectum                         58.3              38.3       47.7                    92.5              58.9         74.5  
C18-21 colorectum and anus                         59.4              40.0       49.1                    94.0              61.1         76.4  
C17-21 intestine                         62.0              41.8       51.3                    97.9              63.9         79.7  
C22 liver and intrahepatic bile ducts                           9.0                3.6         6.2                    14.5                5.8           9.9  
C23 gallbladder                           0.6                1.5         1.1                      1.1                2.6           1.9  
C24 other and unspecified parts of biliary tract                           3.1                2.2         2.6                      5.1                3.6           4.3  
C23-24 gallbladder and biliary tract                           3.8                3.7         3.7                      6.2                6.2           6.2  
C22-24 liver gall bladder and biliary                         12.8                7.3         9.9                    20.6              12.0         16.0  
C25 pancreas                         11.0                9.3       10.2                    18.1              15.3         16.8  
C26 other and ill-defined digestive organs                           1.5                1.2         1.3                      2.6                2.0           2.3  
C30 nasal cavity and middle ear                           0.2                0.3         0.2                      0.3                0.4           0.3  
C31 accessory sinuses                           0.4                0.2         0.3                      0.6                0.4           0.5  
C32 larynx                           5.8                1.2         3.4                      8.3                1.7           4.8  
C00-14 C30-32 all head and neck                         21.0                7.6       14.1                    29.5              10.2         19.4  
C00-15 C32 lip oral pharynx larynx oesophagus                         32.9              12.3       22.3                    47.8              18.3         32.3  
C33 trachea                           0.0                0.1         0.0                      0.0                0.1           0.0  
C34 bronchus and lung                         52.8              40.4       46.1                    86.3              63.5         73.8  
C33-34 lung and trachea                         52.8              40.4       46.1                    86.3              63.6         73.9  
C37 thymus                           0.2                0.2         0.2                      0.2                0.2           0.2  
C38 heart, mediastinum and pleura                           0.5                0.2         0.3                      0.8                0.3           0.5  
C39 other and ill-defined respiratory and intrathoracic                           0.0                  -           0.0                      0.0                  -             0.0  
C40 bone and articular cartilage of limbs                           0.6                0.4         0.5                      0.7                0.4           0.5  
C41 bone and articular cartilage of other and unspecified                           0.9                0.4         0.7                      1.1                0.5           0.8  
C40-41 bone and articular and unspecified                           0.6                0.4         0.5                      0.7                0.4           0.5  
C43 melanoma of skin                         21.2              21.4       21.1                    31.9              28.8         29.9  
C44 other skin                       247.9            163.1     202.3                  406.3            253.3       322.6  
C45 mesothelioma                           1.3                0.3         0.8                      2.4                0.4           1.3  
C46 Kaposi sarcoma                           0.4                0.0         0.2                      0.4                0.0           0.2  
C47 peripheral nerves and autonomic nervous system                           0.2                0.2         0.2                      0.2                0.2           0.2  
C48 retroperitoneum and peritoneum                           0.4                0.7         0.5                      0.6                1.1           0.8  
C49 other connective and soft tissue                           4.4                2.4         3.4                      6.5                3.2           4.7  
C50 breast                           1.3            132.8       68.7                      2.1            171.1         89.8  
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Age-standardised rate (ASR) per 100,000 (estimate)       
Estimated 3-year annual average: 2018-2020 ESP 1976  ESP 2013  
cancer  male   female   all   male   female  all  
C51 vulva 
 
              2.2         1.1  
 
              3.2           1.7  
C52 vagina 
 
              0.6         0.3  
 
              0.8           0.4  
C53 cervix uteri 
 
            11.5         5.9  
 
            12.6           6.4  
C54 corpus uteri 
 
            19.9       10.2  
 
            27.1         14.0  
C55 uterus, part unspecified 
 
              1.0         0.5  
 
              1.5           0.8  
C56 ovary 
 
            13.9         7.2  
 
            19.6         10.3  
C57 other and unspecified female genital organs 
 
              1.9         1.0  
 
              2.8           1.5  
C58 placenta 
 
              0.1         0.0  
 
              0.1           0.0  
C51-52, C55, C57-58 other malignant gynaecological neoplasms 
 
              5.8         3.0  
 
              8.5           4.5  
C60 penis                           1.7  
 
       0.8                      2.6  
 
         1.2  
C61 prostate                       143.4  
 
     69.8                  208.0  
 
     100.0  
C62 testis                           7.2  
 
       3.5                      7.0  
 
         3.4  
C63 other and unspecified male genital organs                           0.1  
 
       0.1                      0.2  
 
         0.1  
C64 kidney, except renal pelvis                         16.7                8.4       12.4                    23.6              12.2         17.7  
C65 renal pelvis                           0.5                0.4         0.5                      0.8                0.6           0.7  
C66 ureter                           0.8                0.3         0.5                      1.4                0.5           0.9  
C64-66 kidney incl. renal pelvis and ureter                         18.0                9.1       13.4                    25.8              13.4         19.3  
C67 bladder                         12.0                4.3         7.8                    21.1                7.2         13.5  
C68 other and unspecified urinary organs                           0.4                0.1         0.3                      0.8                0.2           0.5  
C69 eye and adnexa                           1.3                1.1         1.2                      1.6                1.3           1.5  
C70 meninges                           0.1                0.3         0.2                      0.1                0.6           0.4  
C71 brain                           9.3                6.2         7.7                    12.4                8.1         10.2  
C72 spinal cord, cranial nerves and other parts of CNS                           0.4                0.5         0.5                      0.4                0.5           0.5  
C71-72 brain and spinal cord                           9.7                6.7         8.2                    12.8                8.7         10.6  
C70-72 malignant meninges brain and spinal cord                           9.8                7.1         8.4                    13.0                9.2         11.0  
C70-72, D32-33, D42-43, all meninges brain and CNS                         14.3              14.1       14.2                    18.7              18.2         18.4  
C73 thyroid gland                           2.9                6.9         4.9                      3.5                7.7           5.6  
C74 adrenal gland                           0.4                0.3         0.3                      0.4                0.3           0.4  
C75 other endocrine glands and related structures                           0.5                0.4         0.4                      0.6                0.4           0.5  
C76 other and ill-defined sites                           0.8                0.8         0.8                      1.3                1.2           1.2  
C77 secondary and unspecified lymph nodes                           0.3                0.3         0.3                      0.5                0.4           0.4  
C80 neoplasm without specification of site                           9.1                6.2         7.6                    15.8              11.0         13.2  
C81 Hodgkin lymphoma                           3.5                2.6         3.1                      4.0                2.9           3.4  
C82 follicular nodular non-Hodgkin lymphoma                           4.0                3.5         3.8                      5.5                4.9           5.2  
C83 diffuse non-Hodgkin lymphoma                           8.6                5.7         7.1                    12.9                8.7         10.7  
C84 peripheral and cutaneous T-cell lymphomas                           1.8                1.0         1.3                      2.5                1.3           1.9  
C85 other and unspecified types of non-Hodgkin lymphoma                           3.8                2.9         3.3                      5.9                4.4           5.1  
C82-85 all non-Hodgkin lymphoma                         18.2              13.0       15.5                    26.7              19.4         22.8  
C81-85 lymphoma (total)                         21.8              15.7       18.6                    30.7              22.3         26.3  
C88 immunoproliferative diseases                           0.5                0.2         0.3                      0.8                0.3           0.5  
C90 multiple myeloma                           7.9                4.4         6.1                    12.7                7.1           9.6  
C88-90 multiple myeloma and immunoproliferative                           8.5                4.6         6.4                    13.5                7.3         10.1  
C911 leukaemia CLL                           5.4                2.3         3.8                      8.8                3.8           6.1  
C91 lymphoid leukaemia                           8.1                3.7         5.8                    11.4                5.1           8.0  
C92 myeloid leukaemia                           4.5                2.8         3.6                      7.0                3.8           5.3  
C93 monocytic leukaemia                           0.1                0.1         0.1                      0.1                0.1           0.1  
C94 other leukaemia of specified cell type                           0.2                0.1         0.1                      0.3                0.1           0.2  
C95 leukaemia of unspecified cell type                           0.9                0.5         0.7                      1.8                1.0           1.3  
C91-95 leukaemia (total)                         13.8                7.2       10.3                    20.5              10.1         14.9  
C96 other and unspecified lymphoid haematopoietic                           8.3                5.7         6.9                    12.9                8.4         10.5  
D00 carcinoma in situ of oral cavity, oesophagus and stomach                           0.6                0.5         0.5                      1.0                0.7           0.8  
D01 carcinoma in situ of other and unspecified digestive organs                           0.6                0.4         0.5                      0.8                0.5           0.7  
D02 carcinoma in situ of middle ear and respiratory system                           0.9                0.4         0.7                      1.4                0.6           1.0  
D03 melanoma in situ                         16.6              16.0       16.2                    24.8              21.8         23.0  
D04 carcinoma in situ of skin                         42.0              40.8       41.4                    71.7              70.6         71.2  
D05 carcinoma in situ of breast                           0.1              17.2         8.7                      0.1              19.6         10.0  
D06 carcinoma in situ of cervix uteri 
 
            93.1       47.4  
 
            85.7         43.7  
D07 carcinoma in situ of other and unspecified genital organs                           3.9                2.2         3.1                      4.9                2.6           3.7  
D09 carcinoma in situ of other and unspecified sites                           3.5                1.0         2.2                      5.8                1.6           3.5  
D32 benign meninges                           1.8                4.3         3.1                      2.5                6.1           4.4  
D33 benign brain and other parts of CNS                           1.2                1.1         1.1                      1.4                1.1           1.2  
D32-33 benign meninges, brain & CNS                           2.9                5.4         4.2                      3.9                7.2           5.6  
D35 benign other and unspecified endocrine glands [intracranial only]                           2.1                1.6         1.9                      2.5                1.9           2.2  
D37 uncertain or unknown behaviour of oral cavity and digestive organs                           1.5                1.6         1.6                      2.2                2.3           2.3  
D38 uncertain or unknown of middle ear and respiratory intrathoracic                           0.3                0.2         0.2                      0.3                0.2           0.3  
D39 uncertain or unknown of female genital organs 
 
              3.7         1.9  
 
              4.0           2.1  
D40 uncertain or unknown of male genital organs                           0.1  
 
       0.1                      0.1  
 
         0.0  
D41 uncertain or unknown of urinary organs                           9.6                3.3         6.3                    15.3                4.8           9.7  
D42 uncertain or unknown of meninges                           0.4                0.5         0.4                      0.5                0.6           0.6  
D43 uncertain or unknown of brain and CNS                           1.2                1.2         1.2                      1.3                1.2           1.2  
D42-43 uncertain meninges, brain & CNS                           1.6                1.7         1.6                      1.8                1.8           1.8  
D44 uncertain or unknown of endocrine glands                           0.6                1.0         0.8                      0.7                1.1           0.9  
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Age-standardised rate (ASR) per 100,000 (estimate)       
Estimated 3-year annual average: 2018-2020 ESP 1976  ESP 2013  
cancer  male   female   all   male   female  all  
D47 other uncertain or unknown of lymphoid and haematopoietic                           2.7                2.0         2.3                      4.4                3.1           3.7  
D48 uncertain or unknown of other and unspecified sites                           3.8                2.8         3.2                      6.3                3.2           4.4  
HAEMACARE classification of tumours of lymphatic and haematopoietic tissue        
H01 Lymphoma NOS                           1.3                1.2         1.2                      1.9                1.7           1.8  
H02 NH lymphoma NOS                           2.5                1.6         2.0                      3.8                2.5           3.1  
H03 Composite Hodgkin and Non-Hodgkin                           0.0                0.0         0.0                      0.0                0.0           0.0  
H04 Hodgkin lymphoma nodular lymphocyte predominance                           0.3                0.1         0.2                      0.3                0.1           0.2  
H05 Classical HL                           3.3                2.5         2.9                      3.7                2.8           3.2  
H06 Chronic lymphocytic leukaemia/Small lymphocytic lymphoma                           5.9                2.5         4.1                      9.5                4.1           6.6  
H07 Immunoproliferative diseases                           0.8                0.3         0.5                      1.2                0.5           0.8  
H08 Mantle cell/centrocytic lymphoma                           1.1                0.3         0.7                      1.8                0.5           1.1  
H09 Follicular B lymphoma                           3.3                2.8         3.1                      4.5                4.0           4.2  
H10 Diffuse B lymphoma                           6.3                4.9         5.5                      9.5                7.5           8.4  
H11 Burkitt lymphoma                           0.5                0.1         0.3                      0.5                0.2           0.3  
H12 Marginal zone lymphoma                           0.8                0.8         0.8                      1.1                1.1           1.1  
H13 T lymphoma cutaneous                           0.8                0.4         0.6                      1.0                0.6           0.8  
H14 Other T cell lymphomas                           1.2                0.6         0.9                      1.7                0.9           1.3  
H15 Lymphoblastic lymphoma/Acute precursor cell lymphatic lymphoma                           1.9                1.2         1.5                      1.6                1.0           1.3  
H16 Plasma cell neoplasms                           8.0                4.5         6.1                    12.8                7.1           9.7  
H18 Mature B cell leukaemia hairy cell                           0.6                0.1         0.3                      0.7                0.1           0.4  
H19 Lymphatic leukaemia NOS                           0.0                0.0         0.0                      0.0                0.1           0.0  
H20 Leukaemia NOS                           0.9                0.5         0.7                      1.8                1.0           1.3  
H21 Myeloid leukaemia NOS                           0.1                0.1         0.1                      0.2                0.1           0.1  
H22 Acute myeloid leukaemia                           3.5                2.2         2.8                      5.4                2.9           4.0  
H23 Myeloproliferative neoplasms                           5.6                4.2         4.9                      7.8                5.9           6.7  
H24 Myelodysplastic syndrome                           3.2                1.7         2.4                      5.7                2.9           4.2  
H25 Myelodysplastic, Myeloproliferative neoplasm                           0.7                0.3         0.5                      1.2                0.4           0.7  
C00-96 all cancers excl. NMSC & lung                       425.0            358.6     389.5                  635.3            497.3       561.0  
C00-96 all cancers excl. NMSC & prostate                       334.4            399.1     365.9                  513.6            560.8       534.9  
C00-96 all cancers excl. NMSC & breast                       476.4            266.2     366.9                  719.5            389.7       545.0  
C00-96 all cancers excl. NMSC & breast & prostate                       333.1            266.2     297.2                  511.6            389.7       445.0  
C91-95 leukaemia (total) excl. C911 leukaemia CLL                           8.4                4.9         6.5                    11.8                6.3           8.8  
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Mortality: Annual average over 3 years 
2015-2017 
DEATHS  RATE*/100,000  
Cumulative  
risk# 
of death  
to age 75 
1 in: … 
ICD10 cancer sites  males   females  all   
male 
ESP 
1976  
male 
ESP 
2013  
 female 
ESP 
1976  
female 
ESP 
2013  
  males   females  
C00-96, D00-48 all neoplasms  4,918   4,363   9,280    190.8   342.0   143.7   241.4    9   10  
C00-96 all invasive cancers  4,799   4,264   9,063    186.2   332.4   140.9   235.8    9   11  
C00-14 lip, oral cavity and pharynx  134   54   188    5.4   8.4   1.8   2.9    233   732  
C00-14, C30-32 all head and neck  195   65   260    7.8   12.2   2.2   3.5    161   594  
C00-15, C32 oral cavity, larynx, oesophagus  464   201   665    18.3   29.5   6.4   11.2    72   220  
C15 oesophagus  276   137   412    10.8   17.8   4.3   7.7    125   348  
C16 stomach  202   124   326    7.8   13.6   3.9   7.0    188   452  
C17 small intestine  13   13   26    0.5   0.8   0.4   0.7    2,401   3,135  
C18 colon  272   214   486    10.5   20.0   6.6   12.1    167   260  
C19-21 rectum and anus  334   205   539    12.9   22.7   6.8   11.4    118   209  
C18-21 colorectum and anus  605   420   1,025    23.5   42.6   13.4   23.4    69   116  
C17-21 intestine  618   433   1,051    23.9   43.4   13.8   24.2    67   112  
C22 liver  210   124   334    8.1   13.8   4.0   6.9    170   343  
C23-24 gallbladder and biliary tract  18   38   56    0.7   1.3   1.2   2.2    2,636   1,371  
C22-24 liver and biliary passages  228   162   390    8.8   15.2   5.2   9.1    160   274  
C25 pancreas  276   253   529    10.7   18.7   8.2   14.3    133   173  
C32 larynx  54   11   65    2.1   3.4   0.4   0.6    584   3,270  
C33-34 lung  1,039   845   1,883    40.3   69.0   28.4   47.4    34   46  
C43 melanoma of skin  90   64   154    3.5   5.9   2.0   3.5    436   825  
C45 mesothelioma  34   6   40    1.3   2.2   0.2   0.3    1,174   6,955  
C50 breast  5   719   724    0.2   0.3   24.9   38.6    4,193   56  
C53 cervix   84   84      3.2   4.2     411  
C54 corpus uteri   96   96      3.2   5.4     389  
C56 ovary   290   290      10.1   16.0     125  
C61 prostate  537    537    20.5   44.5      128   
C62 testis  7    7    0.3   0.4      5,282   
C64 kidney  143   73   216    5.6   9.3   2.3   4.1    249   672  
C64-66 kidney, incl. renal pelvis and ureter  151   76   227    5.9   10.0   2.4   4.3    239   650  
C67 bladder  155   67   223    5.9   12.1   2.0   3.8    411   968  
C70-72 malignant meninges, brain & CNS  188   120   308    7.6   10.6   4.5   6.2    160   272  
D32-33 benign brain & CNS  9   13   22    0.4   0.6   0.4   0.7    5,604   5,021  
D42-43 uncertain brain & CNS  8   8   16    0.3   0.6   0.2   0.4    7,801   8,796  
APPENDIX III: MORTALITY 
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Mortality: Annual average over 3 years 
2015-2017 
DEATHS  RATE*/100,000  
Cumulative  
risk# 
of death  
to age 75 
1 in: … 
ICD10 cancer sites  males   females  all   
male 
ESP 
1976  
male 
ESP 
2013  
 female 
ESP 
1976  
female 
ESP 
2013  
  males   females  
C70-72, D32-33, D42-43 all brain & CNS  205   141   346    8.3   11.8   5.1   7.3    152   250  
C73 thyroid  13   17   30    0.5   0.8   0.6   0.9    1,987   2,549  
C81 Hodgkin lymphoma  14   8   22    0.6   0.9   0.3   0.4    2,212   5,328  
C82-85 non-Hodgkin lymphoma  157   125   282    6.0   10.7   3.8   7.0    274   435  
C88-90 multiple myeloma   98   78   176    3.7   7.1   2.4   4.5    463   724  
C91-95 leukaemia  155   102   257    6.0   10.9   3.2   5.7    285   491  
 
Source of data: Central Statistics Office, Ireland 
* Rates are age-standardised to the 1976 and 2013 European Standard Population (ESP) [18] 
# cumulative risk of dying of cancer using method as described [6], expressed as 1 in […], e.g. 1 in 10  
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Table IV-I 
Complete prevalence by cancer type, sex and age:  
number of cancer survivors on 31/12/2018 
site age‡  females %  males  %  all  % 
C01-14 mouth and pharynx <50              189  16%           254  12%           443  13% 
 50+         1,000  84%       1,840  88%       2,840  87% 
          1,188  100%       2,094  100%       3,283  100% 
        
C15 oesophagus <50                 17  3%              49  5%              66  5% 
 50+              490  97%           859  95%       1,349  95% 
               507  100%           908  100%       1,415  100% 
        
C16 stomach <50                 87  10%              85  6%           173  8% 
 50+              771  90%       1,283  94%       2,054  92% 
               859  100%       1,368  100%       2,227  100% 
        
C18-20 colorectum <50              894  9%           677  5%       1,570  7% 
 50+         9,417  91%    11,751  95%    21,167  93% 
       10,310  100%    12,427  100%    22,738  100% 
        
C22 liver  <50                 39  21%              74  14%           113  16% 
 50+              150  79%           453  86%           603  84% 
               189  100%           527  100%           716  100% 
        
C25 pancreas <50                 55  13%              31  7%              86  10% 
 50+              375  87%           399  93%           773  90% 
               430  100%           430  100%           860  100% 
        
C33-34 lung and trachea <50              169  5%           143  4%           312  5% 
 50+         3,193  95%       3,103  96%       6,296  95% 
          3,362  100%       3,246  100%       6,608  100% 
        
C43 melanoma of skin <50         1,798  22%           896  17%       2,694  20% 
 50+         6,558  78%       4,485  83%    11,043  80% 
          8,356  100%       5,381  100%    13,737  100% 
        
C50 breast <50         4,691  11%              18  7%       4,709  11% 
 50+      38,787  89%           253  93%    39,041  89%   
     43,479  100%           271  100%    43,750  100%         
C51-52,C55,C57-58 gynae† <50              159  15% 
  
          159  15%  
50+              929  85% 
  
          929  85%   
        1,087  100% 
  
      1,087  100%         
C53 cervix <50         1,762  37% 
  
      1,762  37%  
50+         2,976  63% 
  
      2,976  63%   
        4,738  100% 
  
      4,738  100%         
C54 corpus uteri <50              237  4% 
  
          237  4%  
50+         5,725  96% 
  
      5,725  96%   
        5,962  100% 
  
      5,962  100%                 
C56 ovary <50              506  16% 
  
          506  16%  
50+         2,681  84% 
  
      2,681  84%   
        3,187  100% 
  
      3,187  100%         
C61 prostate <50 
  
          274  1%           274  1%  
50+ 
  
   39,431  99%    39,431  99%     
   39,705  100%    39,705  100%         
C62 testis <50 
  
      2,438  50%       2,438  50%  
50+ 
  
      2,425  50%       2,425  50%     
      4,863  100%       4,863  100%         
C64 kidney  <50              321  16%           439  13%           760  14%  
50+         1,740  84%       2,853  87%       4,592  86%   
        2,060  100%       3,292  100%       5,352  100%         
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Table IV-I 
Complete prevalence by cancer type, sex and age:  
number of cancer survivors on 31/12/2018 
site age‡  females %  males  %  all  % 
C67 bladder <50                 31  2%              69  2%           100  2%  
50+         1,309  98%       2,975  98%       4,284  98%   
        1,341  100%       3,044  100%       4,384  100%         
C71-72 brain and CNS <50              531  52%           603  52%       1,133  52%  
50+              491  48%           562  48%       1,053  48%   
        1,021  100%       1,164  100%       2,186  100%         
C73 thyroid  <50         1,117  45%           243  33%       1,361  42%  
50+         1,361  55%           505  67%       1,866  58%   
        2,479  100%           748  100%       3,227  100%         
C81 Hodgkin lymphoma <50              740  55%           779  50%       1,519  52%  
50+              618  45%           788  50%       1,406  48%   
        1,358  100%       1,567  100%       2,925  100%         
C82-85 non-Hodgkin  <50              500  13%           769  18%       1,269  16%  
50+         3,304  87%       3,538  82%       6,842  84%   
        3,804  100%       4,308  100%       8,111  100%         
C90 multiple myeloma <50                 35  5%              63  6%              98  5%  
50+              719  95%       1,061  94%       1,781  95%   
             754  100%       1,124  100%       1,879  100%         
C91-95 leukaemia  <50              818  35%           899  26%       1,717  30%  
50+         1,552  65%       2,496  74%       4,048  70% 
  2,370 100% 3,395 100% 5,765 100% 
‡age on 31/12/2018 
†other gynaecological malignancies: vulva, vagina, uterus (NOS) and placenta:  
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Current probability method for lifetime risk of developing cancer 
In previous reports the registry used the ‘cumulative risk’ method to estimate the risk of developing (and dying of) 
any particular cancer up to age 75 [6].  The ‘cumulative risk’ method uses the number of cases of cancer (or cancer 
deaths) and the population estimates for each age band. The ‘cumulative rate’ of developing cancer up to age 75 is 
calculated as sum of the age-specific rates for the first 15 five-year age bands, and the ‘cumulative risk%’= 100*(1-
e-cumulative rate).   
 
When average life expectancy exceeds 75 years, as it does now in Ireland (79.6 years for males and 83.4 for females 
during 2015-2017) [19] this method may under-estimate the true risk of developing cancer during one’s lifetime. 
On the other hand, it may actually over-estimate the risk to age 75 as it does not take into account the attrition 
with increasing age of the ‘at risk’ population as people die. If extended to include all older age-groups, the method 
would over-estimate lifetime risk of cancer for the same reason.  
 
The ‘current probability’ method is considered to be the gold standard of estimating lifetime risk of developing 
cancer [3]. It takes into account the competing risk of dying of non-cancer causes with increasing age and gives a 
better estimate of the lifetime risk of cancer than the ‘cumulative risk’ method. But it still overestimates the 
lifetime risk if the data includes multiple primary cancers; these cases must be excluded from the data. 
 
In this report, the current probability method was used to estimate the lifetime risk of developing cancer, using 
incidence of cancer and risk of death within each 5-year age band (e.g. 0-4, 5-9, 10-14, …, 85-89, 90-94, 95+).  For 
each age-band, adjusting for incremental deaths with increasing age, the risk of developing cancer was calculated. 
The lifetime risk (in %) was computed for men and women for each year (2007-2017) by summing the age-band 
risks up to age 95+. 
 
A lifetime risk of cancer calculator tool was made available by Cancer Research UK [20]. It allows the estimation of 
lifetime risk for any cancer using the ‘current probability’ method with the proviso that the cancer registration data 
excludes multiple primary tumours, and also only the first invasive tumour (per patient) is considered for the 
composite group ‘C00-43 C45-96 all invasive cancers excl. NMSC’.  
 
In summary the Cancer Research UK calculator tool [20] requires three inputs:  
 
Input 1) population 2) all cause  
deaths 
3) cancer  
incidence 
source of data CSO CSO NCRI 
abbreviation pop all_d inc 
age band i 1-20    
1. 0-4    
2. 5-9    
Not shown    
19. 90-94    
20. 95+    
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The three inputs allow calculation of the following output, for each age band i 1-20 
 
output probability  
of dying % 
proportion  
alive% 
person  
years% 
age specific  
rate% 
current  
probability 
abbreviation p_dying alive pers_ yrs agesp_rate 
 
age band i 1-20      
1. 0-4 1-e(-5*all_d/pop) 100.0% 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
2. 5-9 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
not shown      
15. 70-74 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
16. 75-79 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
17. 80-84 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
18. 85-89 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
19. 90-94 1-e(-5*all_d/pop) alivei-1-[alivei-1*p_dying i-1] 5*(alive+alivei+1)/2 inc/pop pers_yrs*agesp_rate/100 
20. 95+ 
 
alivei-1-[alivei-1*p_dying i-1] alive/(all_d/pop) inc/pop pers_yrs*agesp_rate/100 
 
Lifetime risk of developing cancer    = Σ20i=1 current probability 
Risk up to age 75 (75th birthday) of developing cancer = Σ15i=1 current probability 
 
Using data from 2017, the most recent year (at the time of writing) for which both cancer incidence and population 
all-cause mortality data is available from the NCRI and CSO respectively, a comparison of the cumulative risk and 
current probability methods is presented below for the most common cancers. 
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Table V-I 
Risk of developing cancer up to age 75 and over full lifetime using two methods:  
data from cases registered in 2017 
  cumulative risk current probability method   
to age 75 to age 75 lifetime   
% 1 in _ % 1 in _ % 1 in _ 
sex cancer 
      
M  C00-43 C45-96 all invasive cancers excl. NMSC 32.5 3 30.7 3 51.3 2 
M  C01-14 mouth & pharynx 1.2 84 1.0 97 1.4 72 
M  C15 oesophagus 1.1 92 1.0 105 1.6 62 
M  C16 stomach 0.8 120 0.7 137 1.8 56 
M  C18-20 colorectum 4.2 24 3.6 28 7.7 13 
M  C22 liver 0.7 151 0.6 173 1.2 86 
M  C25 pancreas 0.9 108 0.8 126 1.6 62 
M  C33-34 lung 4.4 23 3.7 27 7.4 14 
M  C43 melanoma of skin 1.6 62 1.4 71 2.7 37 
M  C61 prostate 12.8 8 11.9 8 16.8 6 
M C62 testis  0.5   193   0.5   197   0.5   186  
M  C64 kidney 1.4 73 1.2 83 2.0 49 
M  C67 bladder 0.7 144 0.6 168 1.8 56 
M  C71-72 brain & CNS 0.8 132 0.7 146 0.9 108 
M  C81 Hodgkin lymphoma 0.3 361 0.3 386 0.4 272 
M  C82-85 non-Hodgkin lymphoma 1.4 71 1.2 81 2.2 47 
M  C90 multiple myeloma 0.6 162 0.5 197 1.1 89 
M  C91-95 leukaemia  1.0 98 0.9 113 1.7 59 
        
  % 1 in _ % 1 in _ % 1 in _ 
F C00-43 C45-96 all invasive cancers excl. NMSC 26.9 4 25.9 4 44.6 2 
F C01-14 mouth & pharynx 0.5 209 0.4 236 0.6 162 
F C15 oesophagus 0.3 306 0.3 336 0.8 128 
F C16 stomach 0.4 249 0.4 272 0.9 111 
F C18-20 colorectum 2.7 38 2.4 41 5.6 18 
F C22 liver  0.3 407 0.2 449 0.6 170 
F C25 pancreas 0.6 158 0.6 174 1.5 69 
F C33-34 lung  3.5 28 3.2 32 6.2 16 
F C43 melanoma of skin 1.7 60 1.6 64 2.4 41 
F C50 breast 10.0 10 9.7 10 14.0 7 
F C53 cervix uteri 0.9 118 0.8 123 1.0 104 
F C54 corpus uteri 1.9 53 1.7 58 2.4 41 
F C56 ovary 1.2 84 1.1 90 1.9 53 
F C64 kidney 0.7 152 0.6 164 1.1 88 
F C67 bladder 0.3 384 0.2 421 0.7 146 
F C71-72 brain and spinal cord 0.5 203 0.5 215 0.8 132 
F C81 Hodgkin lymphoma 0.2 444 0.2 461 0.3 365 
F C82-85 non-Hodgkin lymphoma 1.2 86 1.1 93 1.9 53 
F C90 multiple myeloma 0.4 288 0.3 321 0.7 148 
F C91-95 leukaemia 0.5 211 0.4 225 0.9 107 
 
 
 
